Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide. However, despite 85% of the world's population living in low- and middle-income countries, 80% of biologics are used in high-income nations.
At last month’s Reuters Pharma Europe conference in Barcelona, pharmaphorum’s Eloise McLennan sat down with Peter Stenico, global head of biosimilars and country president for Sandoz Austria, to talk about the crucial role of biosimilars in promoting health equity and expanding access to life-changing biologics.
Touching on a wide array of topics, Stenico discusses how Sandoz's ACT for Biosimilars initiative aims to achieve 30% usage in 30 countries by 2030, focusing on access, approvability, affordability, and acceptability; and details the importance of education in overcoming fear and uncertainty among healthcare professionals and patients.
Watch the full interview to learn more about Sandoz’ work in driving health equity globally, and why collaborating with policymakers, regulators, and stakeholders is essential to fuel innovation and ensure no patient is left behind.
Subscribe to the pharmaphorum KZfaq channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/